34 research outputs found
Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations
Until recently, estimation of ÎČ-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
The purpose of this study was to examine whether atomoxetine plasma concentration predicts attention-deficit/hyperactivity disorder (ADHD) or oppositional defiant disorder (ODD) response. This post-hoc analysis assessed the relationship between atomoxetine plasma concentration and ADHD and ODD symptoms in patients (with ADHD and comorbid ODD) aged 6â12 years. Patients were randomly assigned to atomoxetine 1.2 mg/kg/day (n = 156) or placebo (n = 70) for 8 weeks (Study Period II). At the end of 8 weeks, ODD non-remitters (score >9 on the SNAP-IV ODD subscale and CGI-I > 2) with atomoxetine plasma concentration <800 ng/ml at 2 weeks were re-randomized to either atomoxetine 1.2 mg/kg/day or 2.4 mg/kg/day for an additional 4 weeks (Study Period III). ODD remitters and non-remitters with plasma atomoxetine â„800 ng/ml remained on 1.2 mg/kg/day atomoxetine for 4 weeks. Patients who received atomoxetine, completed Study Period II, and entered Study Period III were included in these analyses. All the groups demonstrated improvement on the SNAP-IV ODD and ADHD-combined subscales (P < .001). At the end of Study Periods II and III, ODD and ADHD improvement was significantly greater in the remitter group compared with the non-remitter groups. Symptom improvement was numerically greater in the non-remitter (2.4 mg/kg/day compared with the non-remitter 1.2 mg/kg/day) group. Atomoxetine plasma concentration was not indicative of ODD and ADHD improvement after 12 weeks of treatment. ADHD and ODD symptoms improved in all the groups with longer duration on atomoxetine. Results suggest atomoxetine plasma concentration does not predict ODD and ADHD symptom improvement. However, a higher atomoxetine dose may benefit some patients
Modelling human choices: MADeM and decisionâmaking
Research supported by FAPESP 2015/50122-0 and DFG-GRTK 1740/2. RP and AR are also part of the Research, Innovation and Dissemination Center for Neuromathematics FAPESP grant (2013/07699-0). RP is supported by a FAPESP scholarship (2013/25667-8). ACR is partially supported by a CNPq fellowship (grant 306251/2014-0)
From Technological Innovation to âSituatedâ Innovation: Improving the Adaptation of Engineering Training to the Societal Challenges of the 21st Century
International audienc
De lâinnovation technologique Ă lâinnovation « situĂ©e » : pour une meilleure adaptation des formations dâingĂ©nieurs aux dĂ©fis sociĂ©taux du XXIe siĂšcle
International audienc
Genes involved in ER function, ER stress, and Innate Immunity.
<p>Gene expression profiles were derived from three independent human caseous TB granulomas and averaged, then compared to that of uninvolved lung parenchyma. Shown is the fold upregulation as compared to the control (<i>P</i><0.05). All genes listed under no change did not reach statistical significance.</p
ER stress-induced genes are upregulated in human TB granulomas.
<p>RNA isolated from caseous granulomas by laser capture microdissection from 3 TB patients was subjected to microarray analysis. All genes in the database were ranked and a hierarchical list of each gene in relative transcript abundance was created. Shown is a comparison of ER resident genes that that have not been shown to be regulated by ER stress, common innate immune receptors such as scavenger receptors, TLRs, and macrophage markers, and genes known to participate in the Unfolded Protein Response or ER stress pathway. Error bars represent the standard deviation of caseous granulomas from three independent patients compared in the microarray. Genes represented by a red bars had a ranking above 10 and were represented in the top third of all genes in relative transcript abundance, and the genes represented by green bars fell below that threshold.</p